CClinicalTrials.gg
CompletedNCT02694497FemCureUpdated Apr 26, 2018

Transmission of Genital and Extra-genital Chlamydia Trachomatis Infections in Women

An observational study in Chlamydia Trachomatis Infection, sponsored by Maastricht University Medical Center. Completed at 1 site in Netherlands. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-26.

Sponsored by Maastricht University Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
560
Ages
18 Years and older
Sex
Female
01

Study summary

Multicenter prospective cohort study in Chlamydia trachomatis positive women after regular treatment to understand the transmission of anorectal CT infections.

Read the detailed description

Rationale:

Current national and international strategies for the control of Chlamydia trachomatis (CT) critically fail to obtain a reduction in transmission. In women, anorectal infections are about as common as genital CT. Yet anorectal CT remain untested as sexually transmitted infection (STI) clinics, general practitioners, hospital and population testing initiatives largely focus on genital CT. Part of untested anorectal CT is incidentally treated with the treatments applied for genital CT, as in women anorectal CT is often concurrent with genital CT. Yet, it is unknown whether transmission of anorectal CT can still occur after currently recommended treatment. Anorectal and genital CT were observed quite often after regular treatment (up to 40% detection by nucleic acid amplification tests-NAAT). Proposed reasons for such detection include a new (re-)infection from a partner or self-infection from another anatomic, e.g. anorectal, site. Anorectal infections are a potential reservoir for ongoing transmission of genital and anorectal CT in the population, between partners and between anatomic sites of an individual. Yet, neither the transmission potential nor the transmission impact of anorectal infections has been reported. The scientific evidence for the optimal control strategy for anorectal CT and thereby CT in its totality, is lacking.

Objective:

To understand the transmission of anorectal CT infections in women, i.e. from their male sexual partner(s) and from and to the genital region of the same woman, in women who receive routine care, in order to inform guidelines to optimize CT control.

Study population:

Participants are recruited from 3 large Dutch STI clinics, in South Limburg, Amsterdam and Rotterdam. Eligible participants are likely to reflect the STI clinic population, in terms of age, ethnicity and level of education. Participants include genital and/or anorectal CT positive women (n=400).

Study design:

A multicentre prospective cohort study is set up with biological and behavioural measurements after routine treatment of CT. During 3 months, the participants will be studied using a self-administered anorectal and vaginal swab that is self-collected pre-treatment (T0), and at the end of weeks 1, 2, 4, 6, 8, 10, and 12. Samples are tested using NAAT for presence of CT-DNA (detection), concentration (load), viability (weeks 4,8, and 12), and CT type (multilocus sequence typing-MLST) to confirm re-infection. To validate sexual exposure, chromosomal Y DNA (as a marker for semen exposure) in genital and anorectal samples is applied. At each sampling time, online self-administered questionnaires on behaviour (e.g. anorectal exposure) and symptoms will be completed.

Outcomes:

The outcome is detection of anorectal and genital CT at any of the time -points.

Primary outcome is incident detection by NAAT, and secondary outcomes include detection of viable CT and CT-DNA concentration.

Statistical analyses:

In statistical analyses, using logistic regression models, the impact of two key factors will be assessed (i.e. sexual exposure and alternate anatomic site of infection) on detection of anorectal and genital CT. In sub-analyses, the role of treatment-type is evaluated.

Expected results:

This project will provide scientific insight in the role of anorectal CT in maintaining the CT burden, and it will provide practical recommendations (STI guidelines) to reduce avoidable transmission. Implications will be to improve care strategies for (re-)testing and partner management that currently largely neglect anorectal CT, benefitting the individual (better fitting care) and public health (reducing burden) and eventually cost-effectiveness of care.

02

Conditions studied

  • Chlamydia Trachomatis Infection

Keywords

  • transmission
  • women
  • genital
  • anorectal
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 560 is above the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Maastricht University Medical Center is the lead sponsor of 835 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Participants are recruited from 3 large Dutch STI clinics, in South Limburg, Amsterdam and Rotterdam. Eligible participants are likely to reflect the STI clinic population, in terms of age, ethnicity and level of education. Participants include genital and/or anorectal CT positive women (n=400).

Inclusion criteria

  • Chlamydia trachomatis test positive (genital and or anorectal)

Exclusion criteria

Exclusion Criteria:

  • (reported) co-infection with gonorrhoea
  • (reported) co-infection with HIV
  • (reported) co-infection with syphilis
  • (reported) pregnant
  • (reported) anti-Chlamydial antibiotic use (period screening-treatment)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
560 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • OtherChlamydia care as usual
06

What researchers measure

Primary outcomes

  1. Detection of Chlamydia after treatment.

    Detection of anorectal and genital CT by NAAT

    Time frame: 0-12 weeks after regular treatment

Secondary outcomes

  1. Culture of Chlamydia after treatment

    Detection of viable CT

    Time frame: 0-12 weeks after regular treatment

  2. Viability PCR of Chlamydia after treatment

    Detection of viable CT

    Time frame: 0-12 weeks after regular treatment

  3. CT concentration after treatment

    CT-DNA concentration

    Time frame: 0-12 weeks after regular treatment

07

Study locations

1 site
  • Public Health Service South Limburg
    Geleen, South Limburg PO Box 2022, 6160 HA Geleen, Netherlands
08

References and documents

Publications

  • Dukers-Muijrers NH, Wolffs PF, Eppings L, Gotz HM, Bruisten SM, Schim van der Loeff MF, Janssen K, Lucchesi M, Heijman T, van Benthem BH, van Bergen JE, Morre SA, Herbergs J, Kok G, Steenbakkers M, Hogewoning AA, de Vries HJ, Hoebe CJ. Design of the FemCure study: prospective multicentre study on the transmission of genital and extra-genital Chlamydia trachomatis infections in women receiving routine care. BMC Infect Dis. 2016 Aug 8;16:381. doi: 10.1186/s12879-016-1721-x. PubMed 27502928 ↗
  • Janssen KJH, Wolffs PFG, Hoebe CJPA, Heijman T, Gotz HM, Bruisten SM, Schim van der Loeff M, de Vries HJ, Dukers-Muijrers NHTM. Determinants associated with viable genital or rectal Chlamydia trachomatis bacterial load (FemCure). Sex Transm Infect. 2022 Feb;98(1):17-22. doi: 10.1136/sextrans-2020-054533. Epub 2021 Jan 13. PubMed 33441449 ↗
  • Dukers-Muijrers NHTM, Wolffs P, Lucchesi M, Gotz HM, De Vries H, Schim van der Loeff M, Bruisten SM, Hoebe CJPA. Oropharyngeal Chlamydia trachomatis in women; spontaneous clearance and cure after treatment (FemCure). Sex Transm Infect. 2021 Mar;97(2):147-151. doi: 10.1136/sextrans-2020-054558. Epub 2020 Jul 31. PubMed 32737209 ↗
  • Dukers-Muijrers NHTM, Janssen KJH, Hoebe CJPA, Gotz HM, Schim van der Loeff MF, de Vries HJC, Bruisten SM, Wolffs PFG. Spontaneous clearance of Chlamydia trachomatis accounting for bacterial viability in vaginally or rectally infected women (FemCure). Sex Transm Infect. 2020 Nov;96(7):541-548. doi: 10.1136/sextrans-2019-054267. Epub 2020 Feb 17. PubMed 32066588 ↗
  • Dukers-Muijrers NHTM, Wolffs PFG, de Vries HJC, Gotz HM, Janssen K, Hoebe CJPA. Viable Bacterial Load Is Key to Azithromycin Treatment Failure in Rectally Chlamydia trachomatis Infected Women (FemCure). J Infect Dis. 2019 Sep 13;220(8):1389-1390. doi: 10.1093/infdis/jiz267. No abstract available. PubMed 31107956 ↗
  • Dukers-Muijrers NHTM, Wolffs PFG, De Vries H, Gotz HM, Heijman T, Bruisten S, Eppings L, Hogewoning A, Steenbakkers M, Lucchesi M, Schim van der Loeff MF, Hoebe CJPA. Treatment Effectiveness of Azithromycin and Doxycycline in Uncomplicated Rectal and Vaginal Chlamydia trachomatis Infections in Women: A Multicenter Observational Study (FemCure). Clin Infect Dis. 2019 Nov 13;69(11):1946-1954. doi: 10.1093/cid/ciz050. PubMed 30689759 ↗

Individual participant data

Plan to share: Undecided — Not yet

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02694497
Lead sponsor
Maastricht University Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Public Health Service South Limburg, Public Health Service Rotterdam, Public Health Service of Amsterdam, National Institute for Public Health and the Environment (RIVM), STIAIDSNetherlands
Responsible party
Sponsor
First posted
Feb 29, 2016
Start date
Apr 2016
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017
Last update
Apr 26, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion